Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: A 10-year review

Carol Karp, Anat Galor, Sachin Chhabra, Scott D. Barnes, Eduardo C Alfonso

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: To evaluate the biologic effect of subconjunctival recombinant interferon α2b (IFNα2b) for the treatment of ocular surface squamous neoplasia (OSSN). Design: Retrospective study. Participants: Patients with primary or recurrent OSSN treated with subconjunctival injections of recombinant IFNα2b were studied retrospectively. Intervention: Patients were given perilesional subconjunctival injections of 3 million international units in 0.5 ml of IFNα2b (Intron; Schering-Plough, Kenilworth, NJ) until tumor resolution. Main Outcome Measures: Patients were followed up clinically and photographically for evidence of tumor resolution and were monitored for evidence of tumor recurrence. Results: The authors present a series of 15 eyes (14 patients) that were treated with perilesional, subconjunctival, recombinant IFNα2b. Clinical resolution of the tumor occurred in 13 of 15 eyes. The median time to resolution was 1.4 months (range, 0.65.7). In the time of follow-up after lesion resolution (median, 55 months), only 1 of the 15 eyes in the study exhibited disease recurrence, and this occurred 4 months after clinical resolution. Conclusions: Perilesional subconjunctival recombinant IFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate the ideal treatment regimen of IFNα2b. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Original languageEnglish
Pages (from-to)2241-2246
Number of pages6
JournalOphthalmology
Volume117
Issue number12
DOIs
StatePublished - Dec 1 2010

Fingerprint

antineoplaston A10
Interferons
Neoplasms
Recurrence
Injections
Disclosure
Introns
Therapeutics
Retrospective Studies
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia : A 10-year review. / Karp, Carol; Galor, Anat; Chhabra, Sachin; Barnes, Scott D.; Alfonso, Eduardo C.

In: Ophthalmology, Vol. 117, No. 12, 01.12.2010, p. 2241-2246.

Research output: Contribution to journalArticle

@article{7807d2912aaf493d817d7d7064df1bc1,
title = "Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: A 10-year review",
abstract = "Purpose: To evaluate the biologic effect of subconjunctival recombinant interferon α2b (IFNα2b) for the treatment of ocular surface squamous neoplasia (OSSN). Design: Retrospective study. Participants: Patients with primary or recurrent OSSN treated with subconjunctival injections of recombinant IFNα2b were studied retrospectively. Intervention: Patients were given perilesional subconjunctival injections of 3 million international units in 0.5 ml of IFNα2b (Intron; Schering-Plough, Kenilworth, NJ) until tumor resolution. Main Outcome Measures: Patients were followed up clinically and photographically for evidence of tumor resolution and were monitored for evidence of tumor recurrence. Results: The authors present a series of 15 eyes (14 patients) that were treated with perilesional, subconjunctival, recombinant IFNα2b. Clinical resolution of the tumor occurred in 13 of 15 eyes. The median time to resolution was 1.4 months (range, 0.65.7). In the time of follow-up after lesion resolution (median, 55 months), only 1 of the 15 eyes in the study exhibited disease recurrence, and this occurred 4 months after clinical resolution. Conclusions: Perilesional subconjunctival recombinant IFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate the ideal treatment regimen of IFNα2b. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.",
author = "Carol Karp and Anat Galor and Sachin Chhabra and Barnes, {Scott D.} and Alfonso, {Eduardo C}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.ophtha.2010.03.052",
language = "English",
volume = "117",
pages = "2241--2246",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia

T2 - A 10-year review

AU - Karp, Carol

AU - Galor, Anat

AU - Chhabra, Sachin

AU - Barnes, Scott D.

AU - Alfonso, Eduardo C

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Purpose: To evaluate the biologic effect of subconjunctival recombinant interferon α2b (IFNα2b) for the treatment of ocular surface squamous neoplasia (OSSN). Design: Retrospective study. Participants: Patients with primary or recurrent OSSN treated with subconjunctival injections of recombinant IFNα2b were studied retrospectively. Intervention: Patients were given perilesional subconjunctival injections of 3 million international units in 0.5 ml of IFNα2b (Intron; Schering-Plough, Kenilworth, NJ) until tumor resolution. Main Outcome Measures: Patients were followed up clinically and photographically for evidence of tumor resolution and were monitored for evidence of tumor recurrence. Results: The authors present a series of 15 eyes (14 patients) that were treated with perilesional, subconjunctival, recombinant IFNα2b. Clinical resolution of the tumor occurred in 13 of 15 eyes. The median time to resolution was 1.4 months (range, 0.65.7). In the time of follow-up after lesion resolution (median, 55 months), only 1 of the 15 eyes in the study exhibited disease recurrence, and this occurred 4 months after clinical resolution. Conclusions: Perilesional subconjunctival recombinant IFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate the ideal treatment regimen of IFNα2b. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

AB - Purpose: To evaluate the biologic effect of subconjunctival recombinant interferon α2b (IFNα2b) for the treatment of ocular surface squamous neoplasia (OSSN). Design: Retrospective study. Participants: Patients with primary or recurrent OSSN treated with subconjunctival injections of recombinant IFNα2b were studied retrospectively. Intervention: Patients were given perilesional subconjunctival injections of 3 million international units in 0.5 ml of IFNα2b (Intron; Schering-Plough, Kenilworth, NJ) until tumor resolution. Main Outcome Measures: Patients were followed up clinically and photographically for evidence of tumor resolution and were monitored for evidence of tumor recurrence. Results: The authors present a series of 15 eyes (14 patients) that were treated with perilesional, subconjunctival, recombinant IFNα2b. Clinical resolution of the tumor occurred in 13 of 15 eyes. The median time to resolution was 1.4 months (range, 0.65.7). In the time of follow-up after lesion resolution (median, 55 months), only 1 of the 15 eyes in the study exhibited disease recurrence, and this occurred 4 months after clinical resolution. Conclusions: Perilesional subconjunctival recombinant IFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate the ideal treatment regimen of IFNα2b. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=78649810967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649810967&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2010.03.052

DO - 10.1016/j.ophtha.2010.03.052

M3 - Article

C2 - 20619462

AN - SCOPUS:78649810967

VL - 117

SP - 2241

EP - 2246

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 12

ER -